Preclinical models of solid tumors have demonstrated that by administering a more immunogenic lymphodepleting chemotherapy, oxaliplatin in combination with cyclophosphamide, activates tumor macrophages to express T-cell-recruiting chemokines, resulting in improved CAR-T cell infiltration, remodeling of the tumor microenvironment, and increased tumor sensitivity to anti-PD-L1 [45,46]. This evidence concerns the gene CD274 and neoplasm.